Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade Glioma
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify">SAN FRANCISCO, June 26, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the California Institute for Regenerative Medicine (CIRM) has <a href="https:
Overview
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify">SAN FRANCISCO, June 26, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the California Institute for Regenerative Medicine (CIRM) has <a href="https:
Source
Originally published at markets.businessinsider.com.
Related Articles
- Shark is selling a $250 air purifier for $160 during the last hours of Amazon Prime Day
- ROSEN, LEADING TRIAL ATTORNEYS, Encourages Black Rock Coffee Bar, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BRCB
- Not a gig, not a hustle — 25 side income ideas that build over time
